Furthermore, the data indicated that the alterations in ERBB-PI3K pathway were linked to the more advanced stages and the survival of NPC patients with ERBB-PI3K mutations was shorter than the patients without such mutations [25]. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.